Beyond Air, Inc. (XAIR) Stock

Beyond Air, Inc. operates at the intersection of medical devices and biopharmaceuticals, focusing on the advancement of its innovative LungFit platform. This platform serves as a generator and delivery system for nitric oxide, catering to various therapeutic applications. One of its flagship products, LungFit PH, is designed specifically for treating persistent pulmonary hypertension of the newborn, addressing critical medical needs in neonatal care.

Expanding its portfolio, Beyond Air is actively developing LungFit PRO, intended for the treatment of viral lung infections including community-acquired viral pneumonia such as COVID-19, and bronchiolitis in hospitalized patients. Additionally, the company is advancing LungFit GO, aimed at combating nontuberculous mycobacteria infections, thereby broadening its impact across respiratory health challenges.

Formerly known as AIT Therapeutics, Inc., the company rebranded as Beyond Air, Inc. in June 2019, reflecting its commitment to pioneering new frontiers in respiratory care solutions. Headquartered in Garden City, New York, Beyond Air operates with a strategic focus on leveraging its technological innovations to enhance patient outcomes and improve treatment options for respiratory diseases.

Beyond Air, Inc. collaborates with medical professionals and institutions worldwide to drive innovation and expand the application of nitric oxide therapy. Through these partnerships and ongoing research efforts, the company aims to solidify its position as a leader in respiratory health, addressing both acute and chronic conditions with cutting-edge medical technologies.